Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (221-230 of 272) with videos related to

Pageof 28
Sort By:
Clinical Rheumatology|March 13, 2024
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritisProton Rahman, Iain B McInnes, Atul Deodhar, et al.
Lancet (London, England)|July 31, 2022
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trialAtul Deodhar, Filip Van den Bosch, Denis Poddubnyy, et al.
Rheumatology (Oxford, England)|January 11, 2025
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
The Journal of Rheumatology|October 15, 2024
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE StudiesVictoria Navarro-Compán, Martin Rudwaleit, Maureen Dubreuil, et al.
Annals of the Rheumatic Diseases|July 8, 2024
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trialsMatthew A Brown, Martin Rudwaleit, Floris A van Gaalen, et al.
Annals of the Rheumatic Diseases|October 4, 2023
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
RMD Open|November 28, 2025
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studiesHelena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil, et al.
Lancet (London, England)|November 17, 2019
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trialDésirée van der Heijde, In-Ho Song, Aileen L Pangan, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
RMD Open|February 8, 2023
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitisGerd R Burmester, Stanley B Cohen, Kevin L Winthrop, et al.
Pageof 28

Showing results (221-230 of 272) with videos related to

Sort By:
Pageof 28
Clinical Rheumatology|March 13, 2024
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritisProton Rahman, Iain B McInnes, Atul Deodhar, et al.
Lancet (London, England)|July 31, 2022
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trialAtul Deodhar, Filip Van den Bosch, Denis Poddubnyy, et al.
Rheumatology (Oxford, England)|January 11, 2025
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
The Journal of Rheumatology|October 15, 2024
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE StudiesVictoria Navarro-Compán, Martin Rudwaleit, Maureen Dubreuil, et al.
Annals of the Rheumatic Diseases|July 8, 2024
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trialsMatthew A Brown, Martin Rudwaleit, Floris A van Gaalen, et al.
Annals of the Rheumatic Diseases|October 4, 2023
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
RMD Open|November 28, 2025
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studiesHelena Marzo-Ortega, Victoria Navarro-Compan, Maureen Dubreuil, et al.
Lancet (London, England)|November 17, 2019
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trialDésirée van der Heijde, In-Ho Song, Aileen L Pangan, et al.
Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.
RMD Open|February 8, 2023
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitisGerd R Burmester, Stanley B Cohen, Kevin L Winthrop, et al.
Pageof 28